Valneva Recruits IDT Biologika As Manufacturing Partner For Its COVID-19 Vaccine


Valneva SE VALN and IDT Biologika have announced their collaboration to produce Valneva's inactivated COVID-19 vaccine candidate VLA2001. 

  • It follows last week's announcement that Valneva signed an Advance Purchase Agreement with the European Commission to supply up to 60 million doses of VLA2001 over two years.
  • Under the collaboration, IDT Biologika will produce VLA2001's drug substance at its facilities in Dessau-Roßlau, Germany, and Valneva's manufacturing site Livingston, Scotland.
  • Valneva has continued to review its manufacturing strategy following discussions with the UK Government in the summer and again after the termination of the UK contract in September 2021. 
  • Valneva plans to operate a combination of external and internal production of VLA2001 and will further review its manufacturing plans based on demand. 
  • Delivery of the vaccine in Europe is currently expected to begin in April 2022, subject to approval by the European Medicines Agency, which will start a rolling review of VLA2001 shortly.
  • Valneva reported positive Phase 3 results for VLA2001 in October.
  • Price Action: VALN shares are up 12.30% at $66.92 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareContractsMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusDiagnostics
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!